Dec 8, 2016 | Events
From the Coalition to Protect Patient Choice:
“The last panelist was Alex Brill… [who] spoke about FDA reform and specifically about patent issues relating to biologic drugs and their generic counterparts known as biosimilars. He stated that biosimilar entry has not been as robust as was envisioned by the Affordable Care Act, due to archaic regulatory schemes, anticompetitive conduct, and cost-benefit analysis.”
Dec 1, 2016 | Events
From AEI:
“Alex Brill expressed optimism regarding the incoming Congress’ ability to enact pro-growth tax reform and endorsed the Ryan-Brady tax plan. However, he acknowledged that achieving bipartisan cooperation on this front will be challenging.”
Jul 13, 2016 | Events
At an event on promoting economic growth amid a populist backlash, Alex Brill discussed the impact of the corporate tax on workers: “Politicians have used the tax policy debate in campaigns for forever, and they generally use tax policy ideas in a very direct way: ‘My tax plan will affect your tax bill this much — directly.’
Jun 2, 2016 | Events
In an event following the release of FDA’s May 2016 “deeming rule,” which applied tobacco regulations to e-cigarettes, Alex Brill examined Congressional aspects of public policy related to the deeming rule and to e-cigarettes more broadly. Specifically, he looked at what Congress intends to do about e-cigarettes, focusing on three questions: First, what are congressional attitudes about the deeming rule and e-cigarette regulation generally? Second, is it a partisan issue? And third, looking beyond the deeming rule, how will Congress affect e-cigarette use more broadly in the future? “I think that the next battle that Congress will look to tackle with respect to e-cig products is the tax question,” said Brill.
